Metabolic syndrome and renal cell cancer risk in Chinese males: a population-based prospective study.


Session type:


Xin Li1,Gang Wang2,Xiaoshuang Feng1,Zhangyan Lyu1,Luopei Wei1,Yan Wen1,Shuohua Chen3,Shouling Wu3,Hongda Chen1,Ni Li1,Min Dai1,Jie He1
1National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,2Kailuan General Hospital,3Health Department of Kailuan (Group)



Metabolic syndrome (MetS) is now a common public health problem. Few researches have reported the relationship between MetS and the risk of renal cell cancer (RCC). To investigate the association of metabolic syndrome and its components with the risk of RCC in Chinese males, the study was performed in the Kailuan male cohort, a large prospective cohort study.


A total of 104,333 eligible males enrolled in the every 2-year health checkup were involved in the Kailuan male cohort study (2006-2015). Information on demographic and socioeconomic characteristics, lifestyle, medical history and laboratory tests at baseline entry was obtained. Univariable and multivariable Cox proportional hazards regression models were used to estimate the association between MetS and the RCC risk.


During a median follow-up of 8.9 years, 131 RCC cases were verified over a total of 824,211.96 person-years. Among the 5 single MetS components, hypertension (Systolic/diastolic blood pressure≥130/85 mm Hg or antihypertensive drug treatment of previously hypertension) (HR=2.35, 95%CI:1.48-3.72) and elevated triglyceride (TG) (≥1.7mmol/L) (HR=1.78, 95%CI:1.23-2.56) showed significant risk for RCC. Multivariate analysis showed that compared to those who did not meet MetS diagnostic criteria (number of abnormal MetS components<3), HR of RCC risk for participants with MetS was 1.95 (95% CI 1.35–2.83). The number of abnormal MetS components was linearly associated with an increased risk of RCC (P trend<0.001), and the HRs of RCC risk for males with 1, 2 and ≥3 MetS components were 1.27 (0.56–2.90), 2.42 (1.12–5.20) and 3.32 (1.56–7.07), respectively, compared with subjects without MetS components.


MetS might be one of the scientific and important predictors of RCC in males. Controlling metabolic syndrome may potentially have key scientific and clinical significance for RCC prevention.